If you experienced severe vomiting, chronic nausea, dangerous dehydration, or stomach paralysis after using Ozempic or Wegovy, you may have grounds for legal action
Yuan Y et al
Notably, only one registered clinical study exists to date, which evaluates an implant-based delivery system of Exenatide and is currently in Phase 1 with an Active, not recruiting status (NCT05670379), initiated on December 20, 2024, and expected to conclude by August 2025
Contrave may be preferable for patients who can't tolerate injections, prefer oral medication, or have contraindications to GLP-1 receptor agonists
Regular follow-ups with a healthcare provider help track progress, adjust treatment as needed, and ensure results are achieved safely and sustainably